To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
June 7, 2010 > HPV status predicts throat cancer survival
Maura L. Gillison, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘00-‘05) of Ohio State University Comprehensive Cancer Center, Columbus, and colleagues reported that the presence of human papilloma virus (HPV) in tumors is the best predictor of response to therapy and survival for patients with oropharyngeal cancer (cancer of the back of the mouth). Those with HPV-positive tumors had better 3-year rates of overall survival (82.4% vs. 57.1% for patients with HPV-negative tumors). Christine H. Chung, MD (Damon Runyon-Lilly Clinical Investigator ‘05-‘10) of Vanderbilt University School of Medicine, Nashville, was a collaborator on this study. These findings were reported at the American Society of Clinical Oncology conference and in the New England Journal of Medicine.